Affinity Asset Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Affinity Asset Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-100,049	Closed	-$5.88M	–	122
2023 Q4	$5.88M	Buy	100,049 +39,623	+66%	+$2.23M	1.07%	27
2023 Q3	$2.63M	Buy	+60,426	New	+$2.16M	0.74%	41
2022 Q1	–	Sell	-20,000	Closed	-$2.93M	–	77
2021 Q4	$2.93M	Sell	20,000 -7,500	-27%	-$1.16M	1.07%	36
2021 Q3	$4.87M	Buy	+27,500	New	+$4.42M	1.23%	19
2021 Q1	–	Sell	-10,000	Closed	-$2.2M	–	85
2020 Q4	$2.2M	Buy	+10,000	New	+$2.16M	1.16%	26

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Affinity Asset Advisors's MRTX Position: Q1 2024 in Review

Affinity Asset Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 100,049 shares — an estimated $5.88M sold.

Affinity Asset Advisors first reported a position in MRTX in Q4 2020 and held it in 5 quarters. The position peaked at $5.88M in Q4 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

Affinity Asset Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Affinity Asset Advisors sold 100,049 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $5.88M.
Affinity Asset Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2020 and held it in 5 quarters.
Affinity Asset Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $5.88M in Q4 2023.
2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Affinity Asset Advisors's 13F filing for Q1 2024, filed 14 May 2024.